Sindbis Virus Antibody Seroprevalence in Central Plateau Populations, South Africa

Nicole Kennedy, Dominique Goedhals, Sabeehah Vawda, Philip Armand Bester, Felicity Burt

Author affiliations: University of the Free State, Bloemfontein, South Africa (N. Kennedy, D. Goedhals, S. Vawda, P.A. Bester, F. Burt); National Health Laboratory Service, Bloemfontein, South Africa (D. Goedhals, S. Vawda, P.A. Bester, F. Burt)

DOI: https://doi.org/10.3201/eid2810.210869

We report a higher percentage of Sindbis virus-specific IgG in serum from patients attending a rheumatology clinic (18.8%) compared with healthy residents (9.6%) and patients with acute febrile illness (9.4%) in Free State Province, South Africa. Sindbis virus infection should be considered a potential cause of arthritis in South Africa.

Sindbis virus (SINV) is a mosquito-borne virus that belongs to the Togaviridae family; SINV is considered an arthritogenic alphavirus, which is known to cause self-limiting acute febrile illness (AFI) in Africa, Australia, Asia, and Europe and occasional debilitating arthritis that can persist for years after infection (1). Outbreaks are associated with heavy rainfall and temperature changes that favor mosquito breeding. Associations between SINV infection and acute or chronic arthralgia and myalgia have been described in Finland and Sweden (2,3). The extent of chronic debilitating disease caused by SINV in South Africa remains largely unknown.

SINV was identified as a cause of human disease in South Africa in 1963, and subsequent studies confirmed that the virus was present in mosquito populations in the central plateau region, which includes Free State Province (4). We investigated the seroprevalence of SINV in selected human populations of Free State Province. We used an in-house ELISA to detect SINV-specific IgG in serum and confirmed positive serum samples using neutralization assays (Appendix, https://wwwnc.cdc.gov/EID/article/28/10/21-1798-App1.pdf). We screened a total of 568 stored serum samples retrospectively and anonymously. All available stored samples were tested and included 165 serum specimens submitted to the Division of Virology, National Health Laboratory Service, for routine clinical pathology tests from patients who attended the rheumatology clinic at the Universitas Hospital, Bloemfontein, South Africa, during 2013–2017 and 267 serum samples submitted to the National Health Laboratory Service during 2008–2010 from patients with AFI and no confirmed diagnosis. No clinical data were available; however, most attendees at the rheumatology clinic had chronic arthritis. We also included 136 serum samples from healthy volunteers that were collected during 2016–2017 for seroepidemiology studies of Crimean-Congo hemorrhagic fever virus and other vectorborne diseases.

We confirmed 11 serum samples were negative for SINV antibodies using a commercial immunofluorescence assay (Eurolmmun, https://www.eurolimmun.com); these samples were used to determine ELISA cutoff values. Positive control serum was obtained from 1 patient who had a laboratory-confirmed SINV infection. We obtained institutional ethics approval for this study from the Health Sciences Research Ethics Committee, University of the Free State (HSREC approval no. 95/2016C), and informed consent was available for samples collected for the seroepidemiology study (HSREC approval no. 34/2016), negative control serum panel (approval no. ETOVS 152/06), and positive control (approval no. ETOVS 118/06).

We determined optimal reagent dilutions for the ELISA using checkerboard titrations. We diluted serum samples 1:100 and tested for reactions to SINV-
specific and mock antigens (Appendix). We detected reactions using horse radish peroxidase-conjugated antihuman IgG (1:8000) and 2,2′-azino-di-3-ethylbenzthiazoline-6-sulfonate (SeraCare Life Sciences, https://www.seracare.com). We measured optical density (OD) values at 405 nm and calculated net OD values by subtracting each sample OD obtained with mock antigen from the OD value obtained with SINV antigen. To normalize data, percent positivity (PP) for each sample was calculated as PP = (mean net sample OD – mean net OD of the positive control) × 100.

We used the mean PP value ±2 SD for 11 SINV-negative serum samples derived from a total of 83 replicates to determine the cutoff value between positive and negative samples (Appendix). We tested SINV antibody-positive serum samples for neutralizing antibodies using a 50% tissue culture infectious dose serum neutralization assay; samples were considered positive for neutralizing antibodies if the titer was $\geq \log_{10} 1.0$, equal to a serum dilution $\geq 1:10$ (5).

We detected SINV antibodies in 31/165 (18.8%) serum samples from patients who attended the rheumatology clinic, 13/136 (9.6%) samples from residents of SINV-endemic regions (high risk), and 25/267 (9.4%) samples from patients with AFI but no diagnosis (Table). Of the total number of SINV-positive samples, $\approx 45\%$ of the samples were from patients who attended the rheumatology clinic (Table). We detected neutralizing antibodies with endpoint titers ranging from 1:20 to $\geq 1:640$ in 65 of 69 SINV antibody-positive serum samples; 4 samples showed discordant results.

SINV seroprevalence in South Africa for 2006–2009 was 5.4% and increased to 12% after heavy rainfalls in 2010 (6). A 9.4%–9.6% seroprevalence in persons at high risk and for febrile patients is within an expected range, considering that the samples were collected over a 10-year period during which substantial rainfall in Free State Province was associated with arbovirus outbreaks (7,8). Rheumatology clinic attendees had the highest percentage (18.8%) of samples with SINV-specific IgG, compared with 9.4% for residents from SINV-endemic regions and 9.6% for patients with AFI. However, limitations exist when comparing cohorts collected at different time points, and undetected outbreaks might have been responsible for higher seroprevalence among the rheumatology clinic patients. Prospective studies in national tertiary or specialist healthcare clinics should elucidate the contribution of viral infections to chronic arthritis. Our results suggest that associations between SINV infections and arthritis have been underreported in South Africa, and SINV infection should be considered a potential cause of arthritis in this country.

This study was supported by funds from the South African Research Chair in Vectorborne and Zoonotic Diseases (grant no. 98346), which was hosted by the University of the Free State, funded by the Department of Science and Technology, and administered by the National Research Foundation.

### About the Author

Ms. Kennedy is a postgraduate student in the Division of Virology, University of the Free State, Bloemfontein, South Africa. Her research interests focus on arboviruses and the public health implications of arboviral infections.

### References

1. Adams MJ, Lefkowitz EJ, King AMQ, Harrach B, Harrison RL, Knowles NJ, et al. Changes to taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2017). Arch Virol. 2017;162:2505–38. https://doi.org/10.1007/s00705-017-3358-5
2. Kurkela S, Helve T, Vaheeri A, Vapalahti O. Arthritis and arthralgia three years after Sindbis virus infection: clinical follow-up of a cohort of 49 patients. Scand J Infect Dis. 2008;40:167–73. https://doi.org/10.1080/00365540701586996
3. Gyllé Å, Ribers Å, Forsman O, Bucht G, Alenius GM, Wällberg-Jonsson S, et al. Mosquitoborne Sindbis virus infection and long-term illness. Emerg Infect Dis. 2018;24:1141–2. https://doi.org/10.3201/eid2406.170892
4. Jupp PG, Blackburn NK, Thompson DL, Meenahan GM. Sindbis and West Nile virus infections in the Witwatersrand-Pretoria region. S Afr Med J. 1986;70:218–20.
5. Pearce MC, Venter M, Schouwstra T, Van Eeden C, Jansen van Vuren P, Paweska J, et al. Serum neutralising antibody response of seronegative horses against lineage 1 and lineage 2 West Nile virus following vaccination with an
inactivated lineage 1 West Nile virus vaccine. J S Afr Vet Assoc. 2013;84:1–4. https://doi.org/10.4102/jsava.v84i1.1052
6. Storm N, Weyer J, Markotter W, Kemp A, Leman PA, Dermaux-Msimang V, et al. Human cases of Sindbis fever in South Africa, 2006–2010. Epidemiol Infect. 2014;142:234–8. https://doi.org/10.1017/S0950268813000964
7. Archer BN, Thomas J, Weyer J, Cengimbo A, Landoh DE, Jacobs C, et al. Epidemiologic investigations into outbreaks of Rift Valley fever in humans, South Africa, 2008–2011. Emerg Infect Dis. 2013;19:1918–25. https://doi.org/10.3201/eid1912.121527
8. Weyer J, Thomas J, Leman PA, Grobbelaar AA, Kemp A, Paweska JT. Human cases of Wesselsbron disease, South Africa 2010–2011. Vector Borne Zoonotic Dis. 2013;13:330–6. https://doi.org/10.1089/vbz.2012.1181

Address for correspondence: Felicity Burt, Division of Virology, Faculty of Health Sciences, National Health Laboratory Service and University of the Free State, Bloemfontein, 9301, South Africa; email: burtff@ufs.ac.za

April 2021

High-Consequence Pathogens

- Systematic Review of Reported HIV Outbreaks, Pakistan, 2000–2019
- Animal Reservoirs and Hosts for Emerging Alphacoronaviruses and Betacoronaviruses
- Reemergence of Human Monkeypox and Declining Population Immunity in the Context of Urbanization, Nigeria, 2017–2020
- Characteristics of SARS-CoV-2 Transmission among Meat Processing Workers in Nebraska, USA, and Effectiveness of Risk Mitigation Measures
- Blastomycosis Surveillance in 5 States, United States, 1987–2018
- Infections with Tickborne Pathogens after Tick Bite, Austria, 2015–2018
- Epidemiologic and Genomic Reidentification of Yaws, Liberia
- Dynamic Public Perceptions of the Coronavirus Disease Crisis, the Netherlands, 2020
- Sexual Contact as Risk Factor for Campylobacter Infection, Denmark
- COVID-19–Associated Pulmonary Aspergillosis, March–August 2020
- Genomic Surveillance of a Globally Circulating Distinct Group W Clonal Complex 11 Meningococcal Variant, New Zealand, 2013–2018
- Emergence of Burkholderia pseudomallei Sequence Type 562, Northern Australia
- Histopathological Characterization of Cases of Spontaneous Fatal Feline Severe Fever with Thrombocytopenia Syndrome, Japan
- Evolution of Sequence Type 4821 Clonal Complex Hyperinvasive and Quinolone-Resistant Meningococci
- Improving Treatment and Outcomes for Measles in Children, Northern Cambodia, 2009–2018
- Characteristics and Risk Factors of Hospitalized and Nonhospitalized COVID-19 Patients, Atlanta, Georgia, USA, March–April 2020
- Rare Norovirus GIV Foodborne Outbreak, Wisconsin, USA
- Venezuelan Equine Encephalitis Complex Alphavirus in Bats, French Guiana
- Postvaccination COVID-19 among Healthcare Workers, Israel
- SARS-CoV-2 Seropositivity among US Marine Recruits Attending Basic Training, United States, Spring–Fall 2020
- High Case-Fatality Rate for Human Anthrax, Northern Ghana, 2005–2016
- Genomic Analysis of Novel Poxvirus Brazilian Porcupinepox Virus, Brazil, 2019
- Surveillance of COVID-19–Associated Multisystem Inflammatory Syndrome in Children, South Korea
- Fatal Case of Crimean-Congo Hemorrhagic Fever Caused by Reassortant Virus, Spain, 2018
- Stability of SARS-CoV-2 RNA in Nonsupplemented Saliva
- Increased SARS-CoV-2 Testing Capacity with Pooled Saliva Samples
- Persistence of SARS-CoV-2 N-Antibody Response in Healthcare Workers, London, UK
- Highly Pathogenic Avian Influenza Clade 2.3.4.4 Subtype H5N6 Viruses Isolated from Wild Whooper Swans, Mongolia, 2020
- Low-Level Middle East Respiratory Syndrome Coronavirus among Camel Handlers, Kenya, 2019
- Emergence and Polyclonal Dissemination of OXA-244–Producing Escherichia coli, France
- Analysis of Asymptomatic and Presymptomatic Transmission in SARS-CoV-2 Outbreak, Germany, 2020
- Eastern Equine Encephalitis Virus in Mexican Wolf Pups at Zoo, Michigan, USA
- Increased Likelihood of Detecting Ebola Virus RNA in Semen by Using Sample Pelleting

To revisit the April 2021 issue, go to: https://wwwnc.cdc.gov/eid/articles/issue/27/4/table-of-contents
Sindbis Virus Antibody Seroprevalence in Central Plateau Populations, South Africa

Appendix

Materials and Methods

ELISA

We developed and used an in-house ELISA to screen a total of 568 patient serum samples. We prepared SINV-specific antigens from whole cell lysates of SINV-infected Vero cells. Mock antigen was prepared similarly by using uninfected cells. We tested a panel of 11 negative serum samples from volunteers and used a total of 83 replicates to determine the positive versus negative cutoff value for SINV-specific IgG antibodies. We used the mean net optical density (OD) plus 2 SD to determine a cutoff value of 0.253 (Appendix Table 1). To normalize data, we calculated percent positivity (PP) for each sample as PP = (mean net sample OD ÷ mean net OD of the positive control) x 100. The PP was 21.88%. The coefficient of variation for the ELISA was 0.21%. A coefficient of variation of <10% indicated efficient coating of the ELISA plate.

Serum samples tested positive for SINV-specific IgG antibody in 31/165 patients who attended the rheumatology clinic, 13/136 from residents of SINV-endemic regions (high risk), and 25/267 patients with acute febrile illness (AFI) but no diagnosis (Appendix Figure 1, Panels A–C). Approximately 45% of samples that tested positive for SINV-specific IgG antibodies were from patients who attended the rheumatology clinic. Using the Z-test, we found no statistical difference in IgG positivity between samples from the rheumatology clinic and population at high risk or patients with AFI (p>0.05). However, we observed a statistical difference in % of IgG positive samples between residents in SINV-endemic regions and patients with AFI (p<0.05). We observed the highest percentage of SINV-specific IgG positive samples in patients 50–59 years of age who attended the rheumatology clinic (Appendix Table 2), whereas no
specific age group had a higher percentage in the population at high risk for Sindbis virus infection (Appendix Table 3).

**Neutralization Assay**

We confirmed the presence of SINV-specific IgG in serum samples using a neutralization assay. We recorded titers as the reciprocal of the highest serum dilution producing a positive result. Antibody titers of ≥20 were considered positive, and an antibody titer of ≤10 was considered indeterminate. We found detectable neutralizing antibody with a titer ≥20 in 65/69 IgG-positive samples; 1/69 samples was negative, and 3/69 were indeterminate (titer ≤10) (Appendix Figure 2).

**Appendix Table 1.** Cut-off value for SINV-specific IgG antibodies calculated from the negative control serum panel in study of Sindbis virus antibody seroprevalence in central plateau populations, South Africa*

| Serum          | No. replicates | Mean  | SD    | Cut-off value | OD value | PP    |
|----------------|----------------|-------|-------|---------------|----------|-------|
| Negative panel | 83             | 0.057 | 0.098 | 0.253         | 21.88%   |       |

*6 Sindbis virus negative samples tested using 8 replicates each plus 5 negative samples tested using 7 replicates each. OD, optical density; PP, percent positivity.

**Appendix Table 2.** Demographic data and % SINV IgG antibody-positive samples of patients who attended the rheumatology clinic in study of Sindbis virus antibody seroprevalence in central plateau populations, South Africa*

| Age, y†   | Male patients | Female patients |
|-----------|---------------|-----------------|
|           | No. patients  | No. IgG+/no. patients (%) | % IgG+ of total male patients | % IgG+ of M/F patients | No. patients | No. IgG+/no. patients (%) | % IgG+ of total female patients | % IgG+ of M/F patients |
| 0–9       | 1             | 1/1 (100)       | 2.6 | 0.6 | 0 | 0/0 (0) | 0 | 0 |
| 10–19     | 4             | 0/4 (0)         | 0   | 0   | 3 | 0/0 (0) | 0 | 0 |
| 20–29     | 3             | 0/3 (0)         | 0   | 0   | 18 | 2/18 (11.1) | 1.6 | 1.2 |
| 30–39     | 4             | 0/4 (0)         | 0   | 0   | 23 | 4/23 (17.4) | 3.1 | 2.4 |
| 40–49     | 5             | 1/5 (20)        | 2.6 | 0.6 | 23 | 2/23 (8.7) | 1.6 | 1.2 |
| 50–59     | 16            | 6/16 (37.5)     | 15.7 | 3.6 | 38 | 9/38 (23.7) | 7.1 | 5.5 |
| 60–69     | 3             | 1/3 (33.3)      | 2.6 | 0.6 | 14 | 2/14 (14.3) | 1.6 | 1.2 |
| 70–79     | 2             | 1/2 (50)        | 2.6 | 0.6 | 5  | 1/5 (20)  | 0.8 | 0.6 |
| 80–89     | 0             | 0/0 (0)         | 0   | 0   | 3  | 1/3 (33.3) | 0.8 | 0.6 |
| Total†‡   | 38            | 10/38           | –   | –   | 127| 21/127 | –   | –   |

*We used an in-house ELISA to measure Sindbis virus-specific IgG antibodies in patient serum samples. SINV, Sindbis virus.
†The age range for male patients was 0.49–78 years of age and 13–81 years of age for female patients.
‡Of 165 patients, 31 tested positive for SINV-specific IgG antibodies in serum.

**Appendix Table 3.** Age distribution and % SINV IgG antibody positive samples of male residents in SINV-endemic regions in study of Sindbis virus antibody seroprevalence in central plateau populations, South Africa*

| Age group, y† | No. patients | No. IgG+/no. patients (%) | % IgG+ of total no. patients tested |
|---------------|--------------|----------------------------|-----------------------------------|
| 10–19         | 14           | 1/14 (7.1)                 | 0.7                               |
| 20–29         | 43           | 3/43 (7.0)                 | 2.2                               |
| 30–39         | 26           | 3/26 (11.5)                | 2.2                               |
| 40–49         | 29           | 1/29 (3.4)                 | 0.7                               |
| 50–59         | 14           | 3/14 (21.4)                | 2.2                               |
| 60–69         | 7            | 2/7 (28.5)                 | 1.4                               |
| 70–79         | 3            | 0/3 (0)                    | 0                                 |
| Total†        | 136          | 13/136                     | 9.6                               |

*We used an in-house ELISA to measure Sindbis virus-specific IgG antibodies in patient serum samples; all samples were from male patients. SINV, Sindbis virus.
†The age range for male patients was 18–76 years of age.
Appendix Figure 1. Percent positivity values for SINV-specific IgG antibodies in patient serum samples in a study of Sindbis virus antibody seroprevalence in central plateau populations, South Africa. The PP for each sample was calculated as $\text{PP} = \left( \frac{\text{mean net sample OD}}{\text{mean net OD of the positive control}} \right) \times 100$. We calculated a cutoff value of 21.88% that differentiated antibody-positive from antibody-negative samples. A) PP values for patients who attended the arthritis clinic (ARC), B) PP values for residents of SINV-endemic regions with high risk for infection (HSW), and C) PP values for patients with febrile illness (QWF). OD, optical density; PP, percent positivity; SINV, Sindbis virus.
Appendix Figure 2. Antibody titers for 69 SINV-specific IgG-positive serum samples that were tested by using the neutralization assay in a study of Sindbis virus antibody seroprevalence in central plateau populations, South Africa. We recorded titers as the reciprocal of the highest serum dilution producing a positive result. Antibody titers of ≥20 were considered positive, and an antibody titer of ≤10 was considered indeterminate.